Π Π£ΠšΠžΠ’ΠžΠ”Π‘Π’Π’Πž ПО ΠžΡ‚Ρ€Π°ΡΠ»ΡΠΌ

Π’Ρ‹Π±ΠΎΡ€ ΠΏΠ»ΠΎΡ‰Π°Π΄ΠΎΠΊ для клиничСских испытаний с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ИИ

AI tools can help sponsors compare potential trial sites using feasibility, patient availability, investigator experience, facilities, and operational data.

ΠŸΡ€ΠΎΡΠ»ΡƒΡˆΠ°ΠΉΡ‚Π΅ это Ρ€ΡƒΠΊΠΎΠ²ΠΎΠ΄ΡΡ‚Π²ΠΎΠžΠ·Π²ΡƒΡ‡Π΅Π½ΠΎ ИИ Β· ~3 min

На этой страницС3 ΠΌΠΈΠ½ΡƒΡ‚Ρ‹ чтСния
  1. ΠžΠ±Π·ΠΎΡ€
  2. Π“Π»ΡƒΠ±ΠΎΠΊΠΎΠ΅ ΠΏΠΎΠ³Ρ€ΡƒΠΆΠ΅Π½ΠΈΠ΅
  3. РСальная рСализация
  4. The Future of AI Clinical Trial Site Selection
  5. ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π° ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅
  6. ΠŸΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠ°ΠΉΡ‚Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Ρ‚ΡŒ
  7. Часто Π·Π°Π΄Π°Π²Π°Π΅ΠΌΡ‹Π΅ вопросы

ΠžΠ±Π·ΠΎΡ€

A site score does not replace investigator qualification, participant protection, or local feasibility checks. Sponsors should evaluate data quality and avoid allowing historical enrollment patterns to exclude capable sites or underserved communities.

Π“Π»ΡƒΠ±ΠΎΠΊΠΎΠ΅ ΠΏΠΎΠ³Ρ€ΡƒΠΆΠ΅Π½ΠΈΠ΅

Clinical trial site selection asks whether an investigator and site can conduct a particular study safely and reliably. AI can combine feasibility questionnaires, prior performance, geographic data, patient populations, staffing, and facility information to prioritize locations for review. FDA’s E6(R3) Good Clinical Practice guidance says site selection should confirm investigator and site-team qualifications, resources, and facilities appropriate for the trial. A model score alone cannot establish that a site is suitable. Historical recruitment data can reflect which communities were previously approached, not only whether potential participants exist. A ranking model may favor familiar high-volume centers, undercount sites serving rural or underserved populations, or rely on stale estimates. Sponsors should check the protocol’s inclusion criteria, local standard of care, language access, laboratory capacity, and competing studies. Engage investigators directly and verify that the site can protect participants and maintain reliable records. Use AI as a feasibility aid, document the evidence behind recommendations, and allow qualified teams to challenge the ranking. Assess whether the final network covers the population needed for the research question. Site selection is not a prediction contest; trial quality depends on oversight, informed consent, protocol adherence, and participant safety. Reassess feasibility when protocol or site conditions change. The sponsor should consider whether the site can support informed consent in appropriate languages and maintain secure source records. Confirm plans for monitoring, participant reimbursement, and coordination with local care providers where relevant.

РСальная рСализация

A sponsor uses a feasibility model to shortlist sites, then confirms investigator qualifications and resources.

A coordinator checks whether the site can safely conduct the protocol and recruit the intended participants.

A team reviews data completeness and historical enrollment by population before ranking sites.

An investigator clarifies staffing and laboratory capacity during site initiation.

The Future of AI Clinical Trial Site Selection

Trial sponsors may use more real-world and operational data to plan study networks, but responsible selection still requires investigator engagement and protocol-specific checks. Better forecasting could identify capacity gaps earlier, while transparent criteria may help broaden participation. Models should be re-evaluated when trial designs, standards of care, or site resources change. Participant protection remains the primary constraint. Site networks should be reviewed with investigators and community partners as trial needs become clearer. Sponsors should update feasibility when enrollment or operational data arrive.

ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π° ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅

ΠŸΠΎΡ‡Π΅ΠΌΡƒ это Π²Π°ΠΆΠ½ΠΎ

  • ΠšΠΎΠ½Ρ‚Π΅ΠΊΡΡ‚ ΠΈ ΠΏΡ€Π°Π²ΠΈΠ»Π°. ΠžΡ‚Ρ€Π°ΡΠ»Π΅Π²ΠΎΠΉ контСкст опрСдСляСт, Π²Ρ‹ΠΆΠΈΠ²ΡƒΡ‚ Π»ΠΈ ΠΈΠ΄Π΅ΠΈ ИИ ΠΏΡ€ΠΈ ΠΊΠΎΠ½Ρ‚Π°ΠΊΡ‚Π΅ с Ρ€Π΅Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒΡŽ.
  • ΠšΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒ качСства. ΠžΠ³Ρ€Π°Π½ΠΈΡ‡Π΅Π½ΠΈΡ ΠΏΡ€Π΅Π΄ΠΌΠ΅Ρ‚Π½ΠΎΠΉ области Π²Π»ΠΈΡΡŽΡ‚ Π½Π° ΠΏΡ€ΠΈΠ΅ΠΌΠ»Π΅ΠΌΡ‹ΠΉ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ошибок ΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π½Π°Π΄Π·ΠΎΡ€Π°.
  • Π’Ρ‹Π±ΠΎΡ€ сборки. Π£ΡΠΏΠ΅ΡˆΠ½Ρ‹Π΅ развСртывания ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ ΡΠΎΠ³Π»Π°ΡΠΎΠ²Π°Ρ‚ΡŒ тСхничСскиС возмоТности с Ρ€Π°Π±ΠΎΡ‡ΠΈΠΌΠΈ процСссами Π½Π° ΠΏΠ΅Ρ€Π΅Π΄Π½Π΅ΠΌ ΠΊΡ€Π°Π΅.

Π‘Π»Π΅Π΄ΠΈΡ‚Π΅ Π·Π°

  • НормативныС трСбования ΠΌΠΎΠ³ΡƒΡ‚ ΡΠ΄Π΅Π»Π°Ρ‚ΡŒ Π½Π΅Π΄Π΅ΠΉΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌΠΈ ΡΠΈΠ»ΡŒΠ½Ρ‹Π΅ ΠΏΡ€ΠΎΡ‚ΠΎΡ‚ΠΈΠΏΡ‹.
  • Π˜ΡΡ‚ΠΎΡ€ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½Ρ‹Π΅ ΠΌΠΎΠ³ΡƒΡ‚ ΠΎΡ‚Ρ€Π°ΠΆΠ°Ρ‚ΡŒ ΠΏΡ€Π΅Π΄Π²Π·ΡΡ‚ΠΎΡΡ‚ΡŒ, которая наносит Π²Ρ€Π΅Π΄ ΠΊΠΎΠ½ΠΊΡ€Π΅Ρ‚Π½Ρ‹ΠΌ сообщСствам.
  • Π£ΡΡ‚Π°Ρ€Π΅Π²ΡˆΠΈΠ΅ систСмы ΠΌΠΎΠ³ΡƒΡ‚ ΡΠΎΠ·Π΄Π°Π²Π°Ρ‚ΡŒ ΡƒΠ·ΠΊΠΈΠ΅ мСста Π² ΠΈΠ½Ρ‚Π΅Π³Ρ€Π°Ρ†ΠΈΠΈ ΠΈ скрытыС Π·Π°Ρ‚Ρ€Π°Ρ‚Ρ‹.

Π‘Π»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠ΅ шаги

  1. ΠŸΡ€ΠΈΠ²Π»Π΅ΠΊΠ°ΠΉΡ‚Π΅ экспСртов Π² ΠΏΡ€Π΅Π΄ΠΌΠ΅Ρ‚Π½ΠΎΠΉ области ΠΎΡ‚ постановки ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΡ‹ Π΄ΠΎ ΠΎΡ†Π΅Π½ΠΊΠΈ.
  2. Π Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°ΠΉΡ‚Π΅ ΠΆΡƒΡ€Π½Π°Π»Ρ‹ Π°ΡƒΠ΄ΠΈΡ‚Π° ΠΈ Π΄ΠΎΠΊΡƒΠΌΠ΅Π½Ρ‚Π°Ρ†ΠΈΡŽ ΠΏΠ΅Ρ€Π΅Π΄ запуском.
  3. Π—Π°Π±Π»Π°Π³ΠΎΠ²Ρ€Π΅ΠΌΠ΅Π½Π½ΠΎ провСряйтС соотвСтствиС трСбованиям ΠΈ ΠΎΠ±ΡΠ·Π°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° ΠΏΠΎ бСзопасности.
  4. Π Π°Π·Π²Π΅Ρ€Ρ‚Ρ‹Π²Π°Π½ΠΈΠ΅ поэтапно с Ρ‡Π΅Ρ‚ΠΊΠΈΠΌΠΈ критСриями остановки ΠΈ ΠΎΡ‚ΠΊΠ°Ρ‚Π°.

ΠŸΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠ°ΠΉΡ‚Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Ρ‚ΡŒ

БСсплатная рассылка

ΠŸΠΎΠ»ΡƒΡ‡Π°ΠΉΡ‚Π΅ Π΅ΠΆΠ΅Π΄Π½Π΅Π²Π½Ρ‹ΠΉ AI-ΠΎΠ±Π·ΠΎΡ€

Π’Ρ€ΠΈ ΠΏΡ€ΠΎΠ²Π΅Ρ€Π΅Π½Π½Ρ‹Ρ… AI-истории ΠΊΠ°ΠΆΠ΄ΠΎΠ΅ ΡƒΡ‚Ρ€ΠΎ Π±ΡƒΠ΄Π½Π΅Π³ΠΎ дня, написанныС простым английским. БСсплатно навсСгда, Π±Π΅Π· Ρ€Π΅ΠΊΠ»Π°ΠΌΡ‹.

Одно элСктронноС письмо ΠΊΠ°ΠΆΠ΄Ρ‹ΠΉ Π±ΡƒΠ΄Π½ΠΈΠΉ дСнь. ΠžΡ‚ΠΏΠΈΡΠ°Ρ‚ΡŒΡΡ Π² ΠΎΠ΄ΠΈΠ½ ΠΊΠ»ΠΈΠΊ. ΠœΡ‹ Π½ΠΈΠΊΠΎΠ³Π΄Π° Π½Π΅ ΠΏΡ€ΠΎΠ΄Π°Π΅ΠΌ ΠΈ Π½Π΅ ΠΏΠ΅Ρ€Π΅Π΄Π°Π΅ΠΌ ваш адрСс.

ΠŸΡ€ΠΎΠ²Π΅Ρ€ΡŒΡ‚Π΅ сСбя

Take the AI Clinical Trial Site Selection quiz

МгновСнная обратная связь ΠΏΠΎ ΠΊΠ°ΠΆΠ΄ΠΎΠΌΡƒ ΠΎΡ‚Π²Π΅Ρ‚Ρƒ ΠΈ ΠΎΠ±Ρ‰ΠΈΠΉ сСртификат с провСряСмым ΠΈΠ΄Π΅Π½Ρ‚ΠΈΡ„ΠΈΠΊΠ°Ρ‚ΠΎΡ€ΠΎΠΌ послС прохоТдСния курса.

ΠΠ°Ρ‡Π°Ρ‚ΡŒ тСст

ΠŸΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΈΡ‚Π΅ бСсплатноС ΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ Π² области искусствСнного ΠΈΠ½Ρ‚Π΅Π»Π»Π΅ΠΊΡ‚Π°. AI Understanding β€” это нСкоммСрчСская организация 501(c)(3). Никакой Ρ€Π΅ΠΊΠ»Π°ΠΌΡ‹ ΠΈ ΠΏΠ»Π°Ρ‚Π½ΠΎΠ³ΠΎ доступа. Π‘Π΄Π΅Π»Π°Ρ‚ΡŒ ΠΏΠΎΠΆΠ΅Ρ€Ρ‚Π²ΠΎΠ²Π°Π½ΠΈΠ΅

Часто Π·Π°Π΄Π°Π²Π°Π΅ΠΌΡ‹Π΅ вопросы

What is AI Clinical Trial Site Selection?

AI tools can help sponsors compare potential trial sites using feasibility, patient availability, investigator experience, facilities, and operational data. A site score does not replace investigator qualification, participant protection, or local feasibility checks. Sponsors should evaluate data quality and avoid allowing historical enrollment patterns to exclude capable sites or underserved communities.

What is next for AI Clinical Trial Site Selection?

Trial sponsors may use more real-world and operational data to plan study networks, but responsible selection still requires investigator engagement and protocol-specific checks. Better forecasting could identify capacity gaps earlier, while transparent criteria may help broaden participation. Models should be re-evaluated when trial designs, standards of care, or site resources change. Participant protection remains the primary constraint. Site networks should be reviewed with investigators and community partners as trial needs become clearer. Sponsors should update feasibility when enrollment or operational data arrive.

What does a site-selection score establish?

A model ranks candidates but cannot verify suitability alone.

Which option lists the complete site-feasibility set the sponsor should verify after an AI shortlist?

Suitability depends on the particular protocol and local resources.

ΠŸΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠ°ΠΉΡ‚Π΅ ΡƒΡ‡ΠΈΡ‚ΡŒΡΡ

БвязанныС руководства

Π”Ρ€ΡƒΠ³ΠΈΠ΅ руководства, Π²Ρ‹Π±Ρ€Π°Π½Π½Ρ‹Π΅ ΠΏΠΎ этой Ρ‚Π΅ΠΌΠ΅

Π”Π°Π»Π΅Π΅Π‘Π»Π΅Π΄ΡƒΡŽΡ‰Π΅Π΅ руководство

БинтСтичСскиС ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒΠ½Ρ‹Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹ Π² клиничСских испытаниях

ΠžΡ‚Ρ€Π°ΡΠ»ΠΈ

ΠŸΠΎΠ»ΡƒΡ‡ΠΈΡ‚Π΅ бСсплатный AI-ΡΠ΅Ρ€Ρ‚ΠΈΡ„ΠΈΠΊΠ°Ρ‚ΠšΠΎΡ€ΠΎΡ‚ΠΊΠΈΠΉ бСсплатный курс ΠΈ экзамСн. Π‘Π΅Π· стоимости, Π±Π΅Π· ΠΊΠ°Ρ€Ρ‚Ρ‹. Около 2,5 часов.ΠΠ°Ρ‡Π°Ρ‚ΡŒ бСсплатно β†’